CN104159596B - 用于抗血管生成和癌症治疗的α5β1的拮抗剂的给药 - Google Patents

用于抗血管生成和癌症治疗的α5β1的拮抗剂的给药 Download PDF

Info

Publication number
CN104159596B
CN104159596B CN201280070464.9A CN201280070464A CN104159596B CN 104159596 B CN104159596 B CN 104159596B CN 201280070464 A CN201280070464 A CN 201280070464A CN 104159596 B CN104159596 B CN 104159596B
Authority
CN
China
Prior art keywords
vlo4
antagonist
administration
subject
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280070464.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104159596A (zh
Inventor
冯晓东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical College Of North University Of California
Original Assignee
Pharmaceutical College Of North University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical College Of North University Of California filed Critical Pharmaceutical College Of North University Of California
Publication of CN104159596A publication Critical patent/CN104159596A/zh
Application granted granted Critical
Publication of CN104159596B publication Critical patent/CN104159596B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201280070464.9A 2011-12-22 2012-12-18 用于抗血管生成和癌症治疗的α5β1的拮抗剂的给药 Active CN104159596B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/374,369 US8946159B2 (en) 2011-12-22 2011-12-22 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
US13/374,369 2011-12-22
PCT/US2012/070399 WO2013096335A1 (en) 2011-12-22 2012-12-18 Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment

Publications (2)

Publication Number Publication Date
CN104159596A CN104159596A (zh) 2014-11-19
CN104159596B true CN104159596B (zh) 2017-03-08

Family

ID=48655153

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280070464.9A Active CN104159596B (zh) 2011-12-22 2012-12-18 用于抗血管生成和癌症治疗的α5β1的拮抗剂的给药

Country Status (5)

Country Link
US (6) US8946159B2 (cg-RX-API-DMAC7.html)
EP (2) EP2793924B1 (cg-RX-API-DMAC7.html)
JP (1) JP6224615B2 (cg-RX-API-DMAC7.html)
CN (1) CN104159596B (cg-RX-API-DMAC7.html)
WO (1) WO2013096335A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
WO2016029131A1 (en) * 2014-08-22 2016-02-25 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
AU2019234836A1 (en) * 2018-03-13 2020-09-17 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
CN115916176A (zh) 2020-05-01 2023-04-04 加利福尼亚大学董事会 α2β1整联蛋白的抑制剂和其使用方法
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933851A (zh) * 2004-03-24 2007-03-21 Pdl生物制药股份有限公司 使用抗－α5β1抗体抑制癌细胞增殖
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734693A (en) 1992-03-17 1993-10-21 Board Of Regents, The University Of Texas System Neurotrophic peptides
JP2002514605A (ja) * 1998-05-08 2002-05-21 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 血管形成を検出および阻害する方法
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
CA2400040A1 (en) * 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
US20040121031A1 (en) 2002-12-09 2004-06-24 Muhammed Majeed Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin
US7101707B2 (en) 2002-12-23 2006-09-05 Cedars-Sinai Medical Center Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances
CA2560508A1 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EP1898940A4 (en) * 2005-06-07 2010-05-26 Univ Pennsylvania Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS
KR101201886B1 (ko) 2006-01-19 2012-11-15 아이진 주식회사 펩타이드를 유효성분으로 하는 혈관 관련 질환 치료제 조성물
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
EP2268317B1 (en) 2008-03-14 2020-02-26 VisEn Medical, Inc. Integrin targeting agents and in vivo and in vitro imaging methods using the same
US20100105644A1 (en) 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
JP2012510466A (ja) 2008-12-01 2012-05-10 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤
US8987493B2 (en) 2010-05-20 2015-03-24 Temple University—Of the Commonwealth System of Higher Education Process for synthesis of silane dipeptide analogs
US20110311335A1 (en) * 2010-06-21 2011-12-22 Douglas Wike Removable fastener
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
IL210587A0 (en) 2011-01-12 2011-03-31 Adel Jamil Hidmi Natural preparation for treatment of skin sores and lesions
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933851A (zh) * 2004-03-24 2007-03-21 Pdl生物制药股份有限公司 使用抗－α5β1抗体抑制癌细胞增殖
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fibronectin-mediated upregulation of α5β1 integrin and cell adhesion during differentiation of mouse embryonic stem cells;Pimchanok Pimton 等;《Cell Adhesion & Migration》;20111231;第5卷(第1期);第73-82 *
整合素及其拮抗剂的研究进展;孙沛等;《中国药业》;20071231;第16卷(第11期);第1-3页 *

Also Published As

Publication number Publication date
EP2793924A1 (en) 2014-10-29
CN104159596A (zh) 2014-11-19
WO2013096335A1 (en) 2013-06-27
EP3777877B1 (en) 2024-08-07
HK1203391A1 (en) 2015-10-30
US20150105320A1 (en) 2015-04-16
US20130225495A1 (en) 2013-08-29
US20220226431A1 (en) 2022-07-21
US12053504B2 (en) 2024-08-06
EP3777877A1 (en) 2021-02-17
US8815805B2 (en) 2014-08-26
EP2793924A4 (en) 2015-08-26
US20200397856A1 (en) 2020-12-24
US10722555B2 (en) 2020-07-28
JP6224615B2 (ja) 2017-11-01
WO2013096335A8 (en) 2014-03-27
US20240342240A1 (en) 2024-10-17
US11318184B2 (en) 2022-05-03
JP2015506352A (ja) 2015-03-02
US8946159B2 (en) 2015-02-03
US20130165380A1 (en) 2013-06-27
EP2793924B1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
US12053504B2 (en) Anti-angiogenic treatment using VLO4 with a blocking peptide
US20240390458A1 (en) Treatment system for synergistically inhibiting a sprout angiogenesis
US20230021383A1 (en) Spatiotemporal delivery system embedded in 3d-printing
ES2898655T3 (es) Métodos de reparación y regeneración de tejidos
US10993919B2 (en) Chondroprotective nanoparticles for the treatment of osteoarthritis
US20160331853A1 (en) Compositions for radiotherapy and uses thereof
US10925852B2 (en) Talc-bound compositions and uses thereof
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
Sawant et al. Cancer research and therapy: Where are we today
Tiram et al. Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma
US20190216956A1 (en) Compositions for radiotherapy and uses thereof
EP3490615A1 (en) Gel-bound compositions for radiotherapy and uses thereof
HK1203391B (en) Administration of an antagonist of alpha 5 beta1 for anti-antiogenesis and cancer treatment
Liu Dendrimer-based Delivery of Peptides and Antibodies for Choroidal Neovascularization
US20210236668A1 (en) Compositions for radiotherapy and uses thereof
Chaudhari et al. ADVANTAGE OF NANOROBOTS AND USE IN CANCER AND CARDIOVASCULAR DISEASE

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant